- Home
- CYCC vs ICCC Comparison
CYCC vs ICCC Comparison
Compare CYCC & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCC
- ICCC
- Stock Information
- Founded
- CYCC 1992
- ICCC 1982
- Country
- CYCC Malaysia
- ICCC United States
- Employees
- CYCC N/A
- ICCC N/A
- Industry
- CYCC Biotechnology: Pharmaceutical Preparations
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- CYCC Health Care
- ICCC Health Care
- Exchange
- CYCC Nasdaq
- ICCC Nasdaq
- Market Cap
- CYCC 47.6M
- ICCC 48.3M
- IPO Year
- CYCC N/A
- ICCC 1987
- Fundamental
- Price
- CYCC $0.35
- ICCC $5.07
- Analyst Decision
- CYCC Strong Buy
- ICCC
- Analyst Count
- CYCC 1
- ICCC 0
- Target Price
- CYCC $11.00
- ICCC N/A
- AVG Volume (30 Days)
- CYCC 7.1M
- ICCC 33.8K
- Earning Date
- CYCC 05-13-2025
- ICCC 05-14-2025
- Dividend Yield
- CYCC 43.71%
- ICCC N/A
- EPS Growth
- CYCC N/A
- ICCC N/A
- EPS
- CYCC N/A
- ICCC N/A
- Revenue
- CYCC $43,000.00
- ICCC $26,493,169.00
- Revenue This Year
- CYCC $137.21
- ICCC N/A
- Revenue Next Year
- CYCC N/A
- ICCC N/A
- P/E Ratio
- CYCC N/A
- ICCC N/A
- Revenue Growth
- CYCC N/A
- ICCC 51.63
- 52 Week Low
- CYCC $0.17
- ICCC $3.34
- 52 Week High
- CYCC $4.00
- ICCC $5.82
- Technical
- Relative Strength Index (RSI)
- CYCC 65.97
- ICCC 40.88
- Support Level
- CYCC $0.23
- ICCC $4.99
- Resistance Level
- CYCC $0.30
- ICCC $5.72
- Average True Range (ATR)
- CYCC 0.06
- ICCC 0.19
- MACD
- CYCC 0.01
- ICCC -0.05
- Stochastic Oscillator
- CYCC 68.57
- ICCC 14.29
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.